The present invention provides for a fungus, especially in the form of fungal mycelium, that has altered glycogen synthase kinase-3 (GSK-3) expression and/or activity level and therefore exhibits modified characteristics in fruiting body development. Also provided are compositions and methods for generating living fungal mycelium with altered fruiting body development.

The present invention relates to antisense oligonucleotides that are capable of reducing expression of GSK3B in a target cell. The antisense oligonucleotides hybridize to GSK3B pre-mRNA. The present invention further relates to conjugates of the antisense oligonucleotide, pharmaceutical salts and pharmaceutical compositions and methods for treatment or alleviation of conditions such as cancer, inflammatory diseases, neurological diseases, neurological injury, neuronal degeneration, psychiatric diseases and Type 2 diabetes.

The invention in one aspect relates to recombinant replication competent adenovirus that can replicate in and lyse a host cell comprising in the genome of the adenovirus a coding sequence for a glycogen synthase kinase-3 (GSK3) protein operably linked to an expression control sequence. It also relates, among others, to means and methods for treatment of cancer with a coding sequence for a glycogen synthase kinase-3 (GSK3) protein operably linked to an expression control sequence, preferably in the context of an adenovirus. This work was funded in part by European Union Horizon 2020 research and innovation programme, Marie-Sklodowska-Curie grant number 643130.

Methods of inducing cardiomyocytes from induced pluripotent stem cells by contacting induced pluripotent stem cells with silica nanoparticles comprising regulators of canonical Wnt signaling and coated with a biodegradable polymer.

Lateral flow devices, methods and kits for performing lateral flow western blot assays are provided.

The disclosure relates to double stranded ribonucleic acid (dsRNAi) agents and compositions targeting a GSK3? gene, as well as methods of inhibiting expression of a GSK3? gene and methods of treating subjects having a GSK3? associated neurodegenerative disease or disorder, e.g., Fragile X Syndrome, using such dsRNAi agents and compositions.

The present invention provides for a fungus, especially in the form of fungal mycelium, that has altered glycogen synthase kinase-3 (GSK-3) expression and/or activity level and therefore exhibits modified characteristics in fruiting body development. Also provided are compositions and methods for generating living fungal mycelium with altered fruiting body development.

The present invention is directed towards methods for treating non-alcoholic fatty liver disease (NAFLD) in a patient and determining prognosis of NAFLD in a patient.

The invention relates to methods and compositions for regulation of GSK3 activity. The invention provides phosphorylated GSK3 polypeptides and antibodies that recognize such polypeptides. The invention further includes methods for treating disorders that are associated with elevated or reduced GSK3 activity.

Lateral flow devices, methods and kits for performing lateral flow western blot assays are provided.